Xenon Pharmaceuticals Inc. logo XENE - Xenon Pharmaceuticals Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 22
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $85.00 DETAILS
HIGH: $100.00
LOW: $60.00
MEDIAN: $89.50
CONSENSUS: $85.00
UPSIDE: 19.79%

Stock News

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share options and 11,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of July 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Jul 02, 2026 12:01 PM • globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs).

May 29, 2026 12:01 PM • globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

May 29, 2026 12:01 PM • globenewswire.com
Xenon Reports Q1 2026 Financial Results and Provides Business Update

Xenon Reports Q1 2026 Financial Results and Provides Business Update

VANCOUVER, British Columbia and BOSTON, MA, May 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2026 and provided a business update.

May 07, 2026 12:01 PM • globenewswire.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, May 01, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 25,600 share options and 15,000 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of April 30, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

May 01, 2026 12:01 PM • globenewswire.com
Xenon to Report Q1 2026 Financial Results on May 7, 2026

Xenon to Report Q1 2026 Financial Results on May 7, 2026

VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its first quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, May 7, 2026.

Apr 30, 2026 12:01 PM • globenewswire.com
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Xenon's Phase 3 Supports A 'Buy' Despite Its Premium

Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner's differentiated Kv7 mechanism, once-daily dosing, and no-titration profile may help its future adoption, especially for polytreated epilepsy patients. XENE plans its NDA submission in Q3 2026, which would be a key transition toward potential commercialization and revenues.

Apr 22, 2026 12:51 PM • seekingalpha.com
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53. 2% reduction in monthly seizure frequency in 25 mg group vs. 10. 4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physicians VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.

Apr 19, 2026 02:00 PM • globenewswire.com
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting

VANCOUVER, British Columbia and BOSTON, MA, April 19, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today presented positive data from the Phase 3 X-TOLE2 study highlighting the efficacy and safety of azetukalner in focal onset seizures (FOS) at the American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Xenon is also presenting data at the AAN meeting that reinforce the significant opportunity for azetukalner in epilepsy, including 48-month data from the ongoing X-TOLE open-label extension (OLE) study, as well as real-world data reinforcing the potential value that no-titration options like azetukalner would bring to epilepsy management. Azetukalner (AZK) is a novel, potent, KV7 potassium channel opener currently in clinical development for epilepsy and depression.

Apr 19, 2026 02:00 PM • globenewswire.com
Xenon to Present at Upcoming Investor Conferences

Xenon to Present at Upcoming Investor Conferences

VANCOUVER, British Columbia and BOSTON, MA, April 15, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at four upcoming investor conferences in the second quarter of 2026.

Apr 15, 2026 04:30 AM • globenewswire.com
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting

Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures Poster presentations also include long-term efficacy and safety data from X-TOLE open-label extension study of azetukalner, as well as real-world data regarding the burden of titration and need for no-titration options in epilepsy VANCOUVER, British Columbia and BOSTON, MA, April 07, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026 in Chicago, Illinois. Five abstracts will be presented, including a Late-breaking Science oral and poster presentation of the topline Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures (FOS), as well as a poster presentation of long-term 48-month azetukalner data from the X-TOLE open label extension study.

Apr 07, 2026 04:30 AM • globenewswire.com

Price Targets